News | January 28, 2023
Bliss GVS Pharma posts Q3 FY23 consolidated PAT at Rs. 27.94 Cr
The company has reported total income of Rs. 211.36 crores during the period ended December 31, 2022
The company has reported total income of Rs. 211.36 crores during the period ended December 31, 2022
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
Biocon Foundation has pioneered a mHealth-technology-based (mobile health) oral cancer screening program in India
The company has reported total income of Rs. 6848.5 crores during the period ended December 31, 2022
The WHO has urged China to increase adoption of mRNA vaccines, given their high efficacy against variant strains.
SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
Medical Tourism will boost India’s economy
Asthma patients are more likely to have an asthma attack during winter
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
Subscribe To Our Newsletter & Stay Updated
